Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer

Féral, Aurélie; Boone, Mathieu; Lucas, Virginie; Bihan, Céline; Belhout, M.; Chauffert, Bruno; Lenglet, Aurélie

doi:10.1177/10781552211035368

Cited by 4 publications

(3 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, both PSA and testosterone levels indicated stable or improved disease states, supporting stable castration. The high rate of compliance is not completely unexpected, and akin to other oral neoplastic therapy available in oncology, 13 however, this is with the caveat that our study involved patients motivated enough to receive care at a comprehensive cancer center and may not reflect the compliance of a broader community oncology patient population. Regardless, it is reassuring to see that no significant compliance challenges were reported in this population during relugolix therapy.…”

Section: Discussionmentioning

confidence: 95%

A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy

et al. 2023

View full text Add to dashboard Cite

Background Relugolix is the newest form of androgen deprivation therapy (ADT) approved for prostate cancer. However, as an oral drug, several real-world concerns exist, particularly medication compliance, safety with other androgen receptor-targeted agents, and financial burden to patients. Methods A single institution retrospective chart review was conducted evaluating all patients who were prescribed relugolix for any prostate cancer indication from January 1, 2021 to January 31, 2022. Demographic data, cardiac risk factors, concomitant therapy usage, and PSA/testosterone levels, were abstracted from the chart review. Adverse effects were obtained by examining progress notes. Compliance was assessed by clinic notes as well as prescription fills by specialty pharmacy records. The reasons patients did not fill or discontinued the medication were noted. Results Hundred and one patients were prescribed relugolix, and 91 patients consented to research. Seventy-one (78%) patients filled the prescription to relugolix, with a median follow-up of 5 months. Prescription fill data were available for 45 (63%) patients, with 94% of days covered. The most commonly reported reason not to fill was cost at 50%. Sixty-six (93%) patients reported never missing a dose. PSA levels were available in 71 (100%) patients with 69 (97%) showing stable or improved PSA. Testosterone levels were available in 61 (86%) of patients, which showed 61 (100%) stable or successful castration. Twenty-four (34%) patients used relugolix in combination. No new major safety signals were seen in combination therapy. Nineteen (27%) patients had switched to another form of ADT. Fifteen of these (79%) felt similar or better on relugolix therapy. Conclusions Compliance with relugolix seemed acceptable. No major new safety signals were seen, even in combination. Among patients who switched therapy, most tolerated relugolix similarly or better than the previous form of ADT. The cost was a major reason for patients not initiating and for discontinuing therapy.

show abstract

Section: Discussionmentioning

confidence: 95%

A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…There are many studies including various inpatients and outpatients that patient education and pharmaceutical care services make positive contributions to the treatment of oncology patients. [17][18][19][20] However, the results of our study are limited as the study has only focused on the small sample size of cancer patients. On the other hand, two hospital pharmacists were working in the clinic where our study was conducted.…”

Section: Discussionmentioning

confidence: 98%

Assessment of chemotherapy-related educational needs of colorectal cancer patients

Tezcan

Tanır

Yilmaz

et al. 2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Aim Aim of our study was to evaluate cancer patients’ knowledge about their chemotherapy regimens in order to assess educational needs of patients. Methods Study was conducted on 58 colorectal carcinoma patients who were treated in an outpatient chemotherapy unit. These patients had received a 2-page information pamphlet about their chemotherapy treatments before the commencement of treatment. During the first interview with patients, pharmacist collected demographic data and evaluated patients’ knowledge about their medications using a standardized questionnaire. Findings Mean age of the patients was 59.6 ± 1.3 years; 65.5% were male. Majority (77.6%) of patients were graduates of primary school. Sixty-four percent of these had at least one comorbid disease. Median number of chemotherapy courses already received by patients was 4 (1–9). Fifty-nine percent reported that they did not receive any patient education and 43.1% reported that they did not receive any informative document. Twenty-nine percent of patients did not know what actions to take in case of nausea-vomiting; while 53.4% did not know how to react if their body temperature exceeded 38 °C and 25.9% had no idea about dietary necessities. About one-third of patients did not pay attention to oral care. Conclusion Our study showed that patients did not understand (or remember) the basic points about their chemotherapy sufficiently, but remembered the adverse effects they experienced occasionally. Pharmacists will have the chance to increase the level of knowledge of the patients receiving chemotherapy by providing patient education and follow-up.

show abstract

“…OAMs prescription and dispensing have changed in France since this study was performed. Multidisciplinary consultation programs involving the oncologist, the hospital pharmacist, and the nurse have been engaged and can decrease the incidence of adverse events [42]. Most importantly, the French regulation of community pharmacy activities has changed (September 30, 2020), with recognition and funding given to the pharmaceutical support of patients on OAMs, aiming "to make the patient autonomous and an actor in their treatment, limit the loss of reference points for these patients, promote monitoring, proper use and compliance with OAMs, inform the patient and obtain adherence for their treatment, help them in the management of treatments, prevent adverse efects, and provide coordinated patient care" [43].…”

Section: Discussionmentioning

confidence: 99%

Satisfaction of Cancer Patients Treated with Oral Anticancer Medications regarding Dispensing by Community Pharmacists: A Cross-Sectional Study

Balayssac,

Pereira,

Desmard

et al. 2023

European Journal of Cancer Care

View full text Add to dashboard Cite

Purpose. The growing choice of oral anticancer medications (OAMs) delivered in pharmacies puts the patients at the center of their own therapeutic management. Patient satisfaction regarding their pharmaceutical management is particularly important for adherence to their treatment. The aim of this study was to assess the satisfaction of patients treated with OAMs regarding their dispensing in community pharmacies. Methods. A cross-sectional study was conducted with a self-questionnaire proposed to patients in hospital centers and community pharmacies. The patient’s satisfaction regarding pharmacy dispensing was assessed with a visual analogue scale. Answers to questions about the quality of information they received from health professionals were recorded. The patient’s adherence to their medication was assessed with the 8-item Morisky Medication Adherence Scale (MMAS-8). Symptoms and quality of life were recorded with the QLQ-C30 questionnaire. Results. Ninety-one patients were included in the analysis. The median score of satisfaction was 89 (interquartile range: 68, 100), and 49.5% had a satisfaction score ≥90/100. Satisfaction scores were higher for patients reporting information from pharmacists for the method of administration, the management of adverse effects, and drug interactions than for patients reporting no information from pharmacists. Patient satisfaction was not related to MMAS-8 scores, symptoms, or quality of life. Multivariate analysis of patient satisfaction revealed a positive relationship with information on the administration method provided by pharmacists. Conclusions. The level of information provided on OAMs to patients should be the same between pharmacists and oncologists. Good medication dispensing practices by the pharmacist are important components of patient care and satisfaction. We encourage pharmacists to provide more medication information to their patients.

show abstract

Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer

Cited by 4 publications

References 53 publications

A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy

A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy

Assessment of chemotherapy-related educational needs of colorectal cancer patients

Satisfaction of Cancer Patients Treated with Oral Anticancer Medications regarding Dispensing by Community Pharmacists: A Cross-Sectional Study

Contact Info

Product

Resources

About